Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study

A. Cortellini, A. De Giglio, K. Cannita, D.L. Cortinovis, R. Cornelissen, C. Baldessari, R. Giusti, E. D'Argento, F. Grossi, M. Santoni, A. Catino, R. Berardi, V. Sforza, G. Rossi, L. Antonuzzo, V. Di Noia, D. Signorelli, A. Gelibter, M.A. Occhipinti, A. FolladorF. Rastelli, R. Chiari, L.D. Gravara, A. Inno, M. De Tursi, P. Di Marino, G. Mansueto, F. Zoratto, M. Filetti, M. Montrone, F. Citarella, M.V. Pensieri, M. Russano, L. Cantini, O. Nigro, A. Leonetti, P. Bordi, G. Minuti, L. Landi, A. De Toma, C. Donisi, S. Ricciardi, M.R. Migliorino, V.M. Napoli, G. Leone, G. Metro, G.L. Banna, A. Friedlaender, A. Addeo, C. Ficorella, G. Porzio

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)880-889
Number of pages10
JournalThoracic Cancer
Volume12
Issue number6
DOIs
Publication statusPublished - 2021

Keywords

  • immunotherapy
  • non-small cell lung cancer
  • pembrolizumab
  • smoking
  • tobacco

Cite this